Japan’s AMED Seeks New Mindset
This article was originally published in PharmAsia News
Japan's new Agency for Medical Research and Development (AMED) is clear on its main goals but is working to add flesh to the bones as it looks to take a matrix approach to facilitating more collaborative and speedier R&D.
You may also be interested in...
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.